Other Products

PRODUCT	INDICATION OR PROPOSED INDICATION	APPROVED/FILED*		
		U.S.	EU	JAPAN
Myfembree (relugolix, estradiol, and norethindrone acetate)[a]	Moderate to severe pain associated with endometriosis	**Approved** August 2022		
Ngenla (somatrogon)[b]	Pediatric growth hormone deficiency	**Approved** June 2023	**Approved** February 2022	**Approved** January 2022
Prevnar 20/Apexxnar (Vaccine)	Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (adults)	**Approved** June 2021	**Approved** February 2022	
	Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae (pediatric)	**Approved** April 2023		**Filed** March 2023
TicoVac (Vaccine)	Active immunization to prevent tick-borne encephalitis disease	**Approved** August 2021		**Filed** March 2023
Paxlovid[c] **(nirmatrelvir and ritonavir)**	COVID-19 in high-risk adults	**Approved** May 2023	**Approved** February 2023	**Approved** February 2022
Nurtec ODT/Vydura (rimegepant)	Acute treatment of migraine with or without aura (adults)	**Approved** February 2020	**Approved** April 2022	
	Prevention of episodic migraine (adults)	**Approved** May 2021	**Approved** April 2022	
Litfulo/Ritfulo (ritlecitinib)	Alopecia areata	**Approved** June 2023	**Filed** September 2022	**Approved** June 2023
Zavzpret (zavegepant) (intranasal)	Acute treatment of migraine with or without aura (adults)	**Approved** March 2023		
PF-06886992 (Vaccine)	Active immunization to prevent serogroups ABCWY meningococcal infections (adolescent and young adults)	**Filed** December 2022	**Filed** June 2023	
Abrysvo (Vaccine)	Active immunization to prevent respiratory syncytial virus infection (maternal)	**Filed** February 2023	**Filed** January 2023	**Filed** February 2023
	Active immunization to prevent respiratory syncytial virus infection (older adults)	**Approved** May 2023	**Filed** January 2023	**Filed** May 2023
etrasimod	Ulcerative colitis (moderately to severely active)	**Filed** December 2022	**Filed** November 2022	
Braftovi (encorafenib) and Mektovi (binimetinib)	$BRAF^{V600E}$-mutant metastatic non-small cell lung cancer	**Filed** April 2023		
elranatamab (PF-06863135)	Multiple myeloma triple-class relapsed/refractory	**Filed** February 2023	**Filed** February 2023	**Filed** June 2023
Talzenna (talazoparib)	Combination with Xtandi (enzalutamide) for adult patients with homologous recombination repair (HRR) gene-mutated mCRPC[d]	**Approved** June 2023	**Filed** February 2023	
fidanacogene elaparvovec (PF-06838435)[e]	Hemophilia B	**Filed** June 2023	**Filed** June 2023	

* For the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission.

[a] Being developed in collaboration with Sumitomo Pharma America, Inc. (formerly known as Myovant Sciences Ltd.)

[b] Being developed in collaboration with OPKO.

[c] Previously authorized under EUA in the U.S. (December 2021) and approved by the FDA in high-risk adults (May 2023). Remains under EUA for children (12-18 years of age; >88lbs) in the U.S.

[d] Listed patient population applies to U.S. only. Patient population in the filed application in the EU is an all-comers population in men with mCRPC.

[e] Being developed in collaboration with Spark Therapeutics, Inc.

In China, the following products received regulatory approvals in the last twelve months: Xeljanz for the treatment of adult patients with active psoriatic arthritis in October 2022; and Prevenar 13 in infants and children aged 6 weeks to 15 months, in April 2023.